K-252a derivatives for treatment of neurological disorders

• US 5,621,100 A
• Filed: 10/26/1994
• Issued: 04/15/1997
• Est. Priority Date: 07/24/1992
• Status: Expired due to Term

• Current Assignee: Kyowa Hakko Kogyo Company Limited (Kirin Holdings Company Limited), Cephalon Incorporated (Teva Pharmaceutical Industries Limited)
• Original Assignee: Kyowa Hakko Kogyo Company Limited (Kirin Holdings Company Limited), Cephalon Incorporated (Teva Pharmaceutical Industries Limited)
• Inventors: Murakata, Chikara, Kanai, Fumihiko, Kaneko, Masami, Saito, Hiromitsu, Lewis, Michael E., Kauer, James C., Matsuda, Yuzuru, Neff, Nicola, Roberts-Lewis, Jill, Glicksman, Marcie A.
• Primary Examiner(s): Shah, Mukund J.
• Assistant Examiner(s): Sripada, Pavanaram K.
• Application Number:
  US08/329,540
• Time in Patent Office: 902 Days
• Field of Search: 540/545, 514/211
• US Class Current: 540/545
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/407 condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61K 31/553 having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• CPC Class Codes: A61K 31/7056 containing five-membered rings with nitrogen as a ring hetero atom
• CPC Class Codes: C07D 487/14 Ortho-condensed systems

Abstract

The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.

Claims

1. A composition of the formula (II-51):

##STR68## wherein R¹ and R² are CH₂ SC₂ H₅ ;

X is CO₂ CH₃ ;

R is OH; and

Z¹ and Z² are H.